JP6400026B2 - 骨のための生体特異的な薬剤 - Google Patents

骨のための生体特異的な薬剤 Download PDF

Info

Publication number
JP6400026B2
JP6400026B2 JP2015556563A JP2015556563A JP6400026B2 JP 6400026 B2 JP6400026 B2 JP 6400026B2 JP 2015556563 A JP2015556563 A JP 2015556563A JP 2015556563 A JP2015556563 A JP 2015556563A JP 6400026 B2 JP6400026 B2 JP 6400026B2
Authority
JP
Japan
Prior art keywords
bone
biospecific
peptide
agent
contrast agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015556563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509007A (ja
JP2016509007A5 (enExample
Inventor
サンティン，マッテオ
トーマス イクル，スティーブン
トーマス イクル，スティーブン
ムブンディ，ルビンダ
Original Assignee
オーソペディック リサーチ ユーケー
オーソペディック リサーチ ユーケー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーソペディック リサーチ ユーケー, オーソペディック リサーチ ユーケー filed Critical オーソペディック リサーチ ユーケー
Publication of JP2016509007A publication Critical patent/JP2016509007A/ja
Publication of JP2016509007A5 publication Critical patent/JP2016509007A5/ja
Application granted granted Critical
Publication of JP6400026B2 publication Critical patent/JP6400026B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Signal Processing (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Theoretical Computer Science (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2015556563A 2013-02-07 2014-01-31 骨のための生体特異的な薬剤 Active JP6400026B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1302199.3A GB2510587B (en) 2013-02-07 2013-02-07 Biospecific agents for bone
GB1302199.3 2013-02-07
PCT/GB2014/050265 WO2014122431A1 (en) 2013-02-07 2014-01-31 Biospecific agents for bone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018153482A Division JP6683773B2 (ja) 2013-02-07 2018-08-17 骨のための生体特異的な薬剤

Publications (3)

Publication Number Publication Date
JP2016509007A JP2016509007A (ja) 2016-03-24
JP2016509007A5 JP2016509007A5 (enExample) 2017-02-23
JP6400026B2 true JP6400026B2 (ja) 2018-10-03

Family

ID=47998779

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015556563A Active JP6400026B2 (ja) 2013-02-07 2014-01-31 骨のための生体特異的な薬剤
JP2018153482A Active JP6683773B2 (ja) 2013-02-07 2018-08-17 骨のための生体特異的な薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018153482A Active JP6683773B2 (ja) 2013-02-07 2018-08-17 骨のための生体特異的な薬剤

Country Status (9)

Country Link
US (2) US20150367000A1 (enExample)
EP (1) EP2953682B1 (enExample)
JP (2) JP6400026B2 (enExample)
CN (1) CN105142729A (enExample)
CA (1) CA2898366C (enExample)
ES (1) ES2904260T3 (enExample)
GB (1) GB2510587B (enExample)
NZ (1) NZ710436A (enExample)
WO (1) WO2014122431A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3226905T3 (pl) 2014-02-27 2022-04-19 Synartro Ab Koniugaty kwasu hialuronowego z farmaceutycznie aktywnymi substancjami, sposoby i kompozycje
JP7156665B2 (ja) * 2017-06-13 2022-10-19 国立研究開発法人量子科学技術研究開発機構 医薬、並びにその製造方法
CN108187143A (zh) * 2018-02-09 2018-06-22 福州大学 一种兼具磁热效应和原位诱导成骨的多功能复合材料及其制备方法
CN109289119B (zh) * 2018-09-16 2022-05-17 华北理工大学 一种用于脊柱康复系统的磁性纳米粒子球混合物
US11944982B2 (en) 2019-06-05 2024-04-02 Battelle Memorial Institute Polymer-functionalized magnetic particle embodiments for solute separation, and devices and systems for using the same
CN111558041A (zh) * 2020-04-30 2020-08-21 浙江理工大学 羟基磷灰石包裹磁性载药纳米颗粒及其制备方法和在制备骨肉瘤光疗药物中的应用
WO2023041639A2 (fr) * 2021-09-15 2023-03-23 Centre National De La Recherche Scientifique Nanoparticules hybrides
CN117582485B (zh) * 2023-11-15 2024-06-07 湛江中心人民医院 方格星虫三肽在制备骨质疏松药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH694935A5 (de) * 2000-07-26 2005-09-30 Straumann Holding Ag Oberflaechenmodifizierte Implantate.
WO2003072593A2 (en) * 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
CA2554755A1 (en) * 2004-01-28 2005-08-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
CN101155549B (zh) * 2005-03-21 2011-11-16 加利福尼亚大学董事会 官能化磁性纳米颗粒及其使用方法
AU2012204100B2 (en) * 2005-03-21 2014-03-06 The Regents Of The University Of California Functionalized magnetic nanoparticles and methods of use thereof
ES2574810T3 (es) * 2005-09-28 2016-06-22 The Regents Of The University Of California Péptidos de unión a calcio
US20100028387A1 (en) * 2007-06-12 2010-02-04 Ganesan Balasundaram Biocompatible Coated Nanostructured Titanium Surfaces
US8063636B2 (en) * 2009-05-29 2011-11-22 The Invention Science Fund I, Llc Systems, devices, methods, and compositions including targeted ferromagnetic structures
US9316645B2 (en) * 2011-10-07 2016-04-19 Brown University Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging

Also Published As

Publication number Publication date
EP2953682B1 (en) 2021-10-13
EP2953682A1 (en) 2015-12-16
CA2898366C (en) 2021-05-04
GB2510587A (en) 2014-08-13
CA2898366A1 (en) 2014-08-14
GB201302199D0 (en) 2013-03-27
ES2904260T3 (es) 2022-04-04
CN105142729A (zh) 2015-12-09
JP2016509007A (ja) 2016-03-24
GB2510587B (en) 2020-05-20
US11464878B2 (en) 2022-10-11
US20150367000A1 (en) 2015-12-24
WO2014122431A1 (en) 2014-08-14
JP2018199693A (ja) 2018-12-20
NZ710436A (en) 2020-07-31
JP6683773B2 (ja) 2020-04-22
US20200215207A1 (en) 2020-07-09
HK1217910A1 (zh) 2017-01-27

Similar Documents

Publication Publication Date Title
JP6400026B2 (ja) 骨のための生体特異的な薬剤
US8945526B2 (en) Amphiphilic substance, and drug delivery system and molecular imaging system using the same
Park et al. A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides
Qi et al. Folate receptor-targeted dendrimer-methotrexate conjugate for inflammatory arthritis
Lee et al. Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin
US20120107229A1 (en) Novel nano-probes for molecular imaging and targeted therapy of diseases
Tao et al. A novel biocompatible, simvastatin-loaded, bone-targeting lipid nanocarrier for treating osteoporosis more effectively
WO2018103660A1 (zh) Vap多肽及其在制备靶向诊疗肿瘤药物中的应用
Cherri et al. Biodegradable dendritic polyglycerol sulfate for the delivery and tumor accumulation of cytostatic anticancer drugs
US20130302255A1 (en) Novel targeted paramagnetic contrast agent
CN111821470A (zh) 包载甲氨蝶呤的铁-鞣酸配合物及其制备方法与应用
KR101093549B1 (ko) 질환의 진단을 위한 표적 펩타이드가 결합된 양친성 키토산나노입자 조영제
AU2006200363A1 (en) Glycopeptide compositions
JP2002504927A (ja) デキストラン担持白金化合物を使用する腫瘍のｘ線造影
KR101675948B1 (ko) 동맥경화 진단용 키토산 나노입자 복합체, 이의 제조방법 및 이를 포함하는 조영제 조성물
Rasouli et al. 99mTc-anionic linear globular dendrimer-G2-phenylalanine conjugate: Novel brain tumor SPECT imaging
Jirátová et al. Biological characterization of a novel hybrid copolymer carrier system based on glycogen
CN113827593B (zh) 角鲨烯化西达本胺前药自组装纳米粒及制备方法与应用
CN117563012A (zh) 一种多肽偶联物及制备方法和应用
KR102358116B1 (ko) 기체 발포형 마이셀 및 이의 제조방법
HK1217910B (en) Biospecific agents for bone
KR20180107745A (ko) 기체 발포형 마이셀 및 이의 제조방법
CN111840324B (zh) 应用于骨肉瘤细胞成像或治疗的Au DENPs-巨噬细胞复合物
US20120277409A1 (en) Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy
Tao et al. A Biocompatible, Simvastatin-Loaded, Bone-Targeting Lipid Nanocarrier: Breaking the'Traditional Shackle'to Treat Osteoporosis More Effectively

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180404

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180904

R150 Certificate of patent or registration of utility model

Ref document number: 6400026

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250